CA2389173A1 - Agent for treating hepatitis c - Google Patents
Agent for treating hepatitis c Download PDFInfo
- Publication number
- CA2389173A1 CA2389173A1 CA002389173A CA2389173A CA2389173A1 CA 2389173 A1 CA2389173 A1 CA 2389173A1 CA 002389173 A CA002389173 A CA 002389173A CA 2389173 A CA2389173 A CA 2389173A CA 2389173 A1 CA2389173 A1 CA 2389173A1
- Authority
- CA
- Canada
- Prior art keywords
- ukrain
- patients
- ifn
- doses
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 241001233914 Chelidonium majus Species 0.000 claims abstract description 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930013930 alkaloid Natural products 0.000 claims description 7
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 108010047761 Interferon-alpha Proteins 0.000 claims description 3
- 102000006992 Interferon-alpha Human genes 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims 1
- 239000012084 conversion product Substances 0.000 abstract 1
- 208000013772 cryohydrocytosis Diseases 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000003928 amperometric titration Methods 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KIGCDEJCMKDBHU-NIQQUOCOSA-K ukrain Chemical compound [OH-].[OH-].[OH-].C([C@H](O)[C@@H]1C2=CC=C3OCOC3=C2C2)C3=CC=4OCOC=4C=C3[C@H]1[N+]2(C)CCNP(=S)(NCC[N+]1(C)[C@@H]2C3=CC=4OCOC=4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1)NCC[N+]1(C)[C@@H]2C3=CC(OCO4)=C4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1 KIGCDEJCMKDBHU-NIQQUOCOSA-K 0.000 description 2
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- -1 alkaloid phosphorus derivatives Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000025517 cannabinoid hyperemesis syndrome Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA481/2000 | 2000-03-22 | ||
AT0048100A AT408719B (de) | 2000-03-22 | 2000-03-22 | Mittel zur behandlung von hepatitis c |
PCT/AT2001/000076 WO2001070203A2 (de) | 2000-03-22 | 2001-03-20 | Mittel zur behandlung von hepatitis c, enthaltend ukrain |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2389173A1 true CA2389173A1 (en) | 2001-09-27 |
Family
ID=3674939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002389173A Abandoned CA2389173A1 (en) | 2000-03-22 | 2001-03-20 | Agent for treating hepatitis c |
Country Status (17)
Country | Link |
---|---|
JP (1) | JP2003527414A (ru) |
KR (1) | KR20020087045A (ru) |
CN (1) | CN1416347A (ru) |
AT (1) | AT408719B (ru) |
AU (1) | AU2001239000A1 (ru) |
BG (1) | BG107088A (ru) |
BR (1) | BR0107211A (ru) |
CA (1) | CA2389173A1 (ru) |
EA (1) | EA200200584A1 (ru) |
HR (1) | HRP20020367A2 (ru) |
IL (1) | IL149314A0 (ru) |
IS (1) | IS6360A (ru) |
MA (1) | MA25509A1 (ru) |
MX (1) | MXPA02004993A (ru) |
NO (1) | NO20022253L (ru) |
PL (1) | PL365000A1 (ru) |
WO (1) | WO2001070203A2 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH695417A5 (de) * | 2001-11-15 | 2006-05-15 | Ddr Wassyl Nowicky Dipl Ing | Verfahren zur Umsetzung von Alkaloiden. |
EP1459753A1 (en) | 2003-03-18 | 2004-09-22 | Nowicky, Wassyl, Dipl.-Ing. DDr. | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the manufacture of medicaments |
WO2008039179A1 (en) * | 2006-09-26 | 2008-04-03 | Addiction Research Institute, Inc. | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c |
CN106343303A (zh) * | 2015-07-13 | 2017-01-25 | 张如安 | 灭杀乙肝病毒的饮料 |
CN106109538A (zh) * | 2016-07-29 | 2016-11-16 | 桂林淮安天然保健品开发有限公司 | 治疗丙肝的药物组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3128018A1 (de) * | 1981-07-13 | 1983-04-07 | Wassyl 1060 Wien Nowicky | "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze" |
US4970212A (en) * | 1982-05-18 | 1990-11-13 | Nowicky Wassili | Method of treating human illnesses which compromise the ability to mount an effective immunological response |
US4816462A (en) * | 1982-05-18 | 1989-03-28 | Nowicky Wassili | Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds |
PT93772A (pt) * | 1989-04-17 | 1991-01-08 | Searle & Co | Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer |
-
2000
- 2000-03-22 AT AT0048100A patent/AT408719B/de not_active IP Right Cessation
-
2001
- 2001-03-20 AU AU2001239000A patent/AU2001239000A1/en not_active Abandoned
- 2001-03-20 WO PCT/AT2001/000076 patent/WO2001070203A2/de active Application Filing
- 2001-03-20 PL PL01365000A patent/PL365000A1/xx not_active Application Discontinuation
- 2001-03-20 BR BR0107211-0A patent/BR0107211A/pt not_active IP Right Cessation
- 2001-03-20 IL IL14931401A patent/IL149314A0/xx unknown
- 2001-03-20 MX MXPA02004993A patent/MXPA02004993A/es unknown
- 2001-03-20 CA CA002389173A patent/CA2389173A1/en not_active Abandoned
- 2001-03-20 CN CN01803046A patent/CN1416347A/zh active Pending
- 2001-03-20 EA EA200200584A patent/EA200200584A1/ru unknown
- 2001-03-20 KR KR1020027005739A patent/KR20020087045A/ko not_active Application Discontinuation
- 2001-03-20 JP JP2001568401A patent/JP2003527414A/ja active Pending
-
2002
- 2002-04-24 IS IS6360A patent/IS6360A/is unknown
- 2002-04-26 HR HR20020367A patent/HRP20020367A2/hr not_active Application Discontinuation
- 2002-05-10 NO NO20022253A patent/NO20022253L/no unknown
- 2002-05-28 MA MA26657A patent/MA25509A1/fr unknown
- 2002-09-12 BG BG107088A patent/BG107088A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
NO20022253D0 (no) | 2002-05-10 |
AU2001239000A1 (en) | 2001-10-03 |
BR0107211A (pt) | 2004-01-06 |
HRP20020367A2 (en) | 2004-02-29 |
MXPA02004993A (es) | 2003-10-14 |
CN1416347A (zh) | 2003-05-07 |
KR20020087045A (ko) | 2002-11-21 |
IS6360A (is) | 2002-04-24 |
EA200200584A1 (ru) | 2003-06-26 |
NO20022253L (no) | 2002-05-10 |
AT408719B (de) | 2002-02-25 |
MA25509A1 (fr) | 2002-07-01 |
WO2001070203A2 (de) | 2001-09-27 |
BG107088A (en) | 2003-05-30 |
PL365000A1 (en) | 2004-12-27 |
JP2003527414A (ja) | 2003-09-16 |
ATA4812000A (de) | 2001-07-15 |
WO2001070203A3 (de) | 2002-09-06 |
IL149314A0 (en) | 2002-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100638684B1 (ko) | 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도 | |
US6007805A (en) | Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver | |
KR20010052622A (ko) | 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도 | |
US20060194835A1 (en) | Compositions and methods for treating or preventing flaviviridae infections | |
JP2005506957A (ja) | ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンb12およびインターフェロンを用いた複合治療 | |
CZ281663B6 (cs) | Farmaceutický prostředek pro léčení T-buněčné leukemie (lymfomu dospělých) | |
US20070015803A1 (en) | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | |
JP4594734B2 (ja) | C型肝炎、牛ウイルス性下痢症及び豚コレラウイルスを含むフラビウイルス科ウイルスにより生起される感染症の治療のためのエンドペルオキシド類の使用 | |
CZ20011130A3 (cs) | Sloučenina, farmaceutický prostředek a jejich použití pro ribavirin-interferon alfa kombinovanou terapii | |
WO2004078193A1 (en) | Interferon drug therapy for the treatment of viral diseases and liver fibrosis | |
RU2730998C2 (ru) | Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении | |
CA2389173A1 (en) | Agent for treating hepatitis c | |
EP1809276A2 (en) | Treatment method | |
WO1994001125A9 (en) | Composition and method of treating hepatitis b | |
WO1994001125A1 (en) | Composition and method of treating hepatitis b | |
WO2016090107A2 (en) | Treatment of hepatitis delta virus infection | |
EP1596883A1 (en) | Interferon drug therapy for the treatment of viral diseases and liver fibrosis | |
CA2614639C (en) | Pharmaceutical composition for treatment of blood clotting disorder | |
CN111632150A (zh) | 一种治疗肾病综合征的药物组合物 | |
WO1992004027A1 (en) | Pharmaceutical compositions for use in treating aids | |
US20220185823A1 (en) | Prevention, Prophylactic and Therapeutic Treatment of Autoimmune Diseases Including Multiple Sclerosis Using Novel Small Molecules and Compositions Thereof | |
EP0116238A1 (en) | Therapeutic compositions and their use in enhancing brain function | |
WO1991004047A1 (en) | Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines | |
JPH0867637A (ja) | 肝疾患予防治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20040322 |